Kindred Biosciences (Kindred Biosciences) FCF Margin % : -76.62% (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kindred Biosciences's Free Cash Flow for the three months ended in Jun. 2021 was $-2.71 Mil. Kindred Biosciences's Revenue for the three months ended in Jun. 2021 was $3.54 Mil. Therefore, Kindred Biosciences's FCF Margin % for the quarter that ended in Jun. 2021 was -76.62%.

As of today, Kindred Biosciences's current FCF Yield % is -7.88%.

The historical rank and industry rank for Kindred Biosciences's FCF Margin % or its related term are showing as below:

KIN' s FCF Margin % Range Over the Past 10 Years
Min: -379.66 Med: 0 Max: 0
Current: -379.66

KIN's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: -0.675 vs KIN: -379.66

Kindred Biosciences FCF Margin % Historical Data

The historical data trend for Kindred Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindred Biosciences FCF Margin % Chart

Kindred Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

FCF Margin %

Get a 7-Day Free Trial

-2,998.68

-1,521.85

-32.01

Kindred Biosciences Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
FCF Margin %	Get a 7-Day Free Trial															57.50	-1,012.37	-752.68	-403.55	-76.62

Competitive Comparison of Kindred Biosciences's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Kindred Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kindred Biosciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kindred Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kindred Biosciences's FCF Margin % falls into.

Kindred Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kindred Biosciences's FCF Margin for the fiscal year that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2020 )	/	Revenue (A: Dec. 2020 )
	=	-13.495	/	42.164
	=	-32.01 %

Kindred Biosciences's FCF Margin for the quarter that ended in Jun. 2021 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2021 )	/	Revenue (Q: Jun. 2021 )
	=	-2.71	/	3.537
	=	-76.62 %

Kindred Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindred Biosciences (Kindred Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010

Website

https://www.kindredbio.com

Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.

Executives

Richard Chin	director, officer: Chief Executive Officer	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee	officer: Chief Financial Officer	C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken	director	C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery	director	C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof	officer: SVP of Regulatory Affairs	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley	officer: Chief Commercial Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker	officer: Chief Financial Officer	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010